VanEck Pharmaceutical ETF
PPH
49 hedge funds and large institutions have $206M invested in VanEck Pharmaceutical ETF in 2019 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 8 increasing their positions, 13 reducing their positions, and 5 closing their positions.
120% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 5
59% more capital invested
Capital invested by funds: $129M → $206M (+$76.6M)
48% more call options, than puts
Call options by funds: $2.61M | Put options by funds: $1.76M
14% more funds holding
Funds holding: 43 → 49 (+6)
7.66% more ownership
Funds ownership: 94.95% → 102.62% (+7.7%)
38% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$68.3M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$36.4M |
| 3 |
WWM
Western Wealth Management
Golden,
Colorado
|
+$4.45M |
| 4 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
+$861K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$745K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$48.3M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$9.04M |
| 3 |
JP Morgan Chase
New York
|
-$5.74M |
| 4 |
Goldman Sachs
New York
|
-$1.21M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.09M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
51
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$1.09M | -18,133 | Closed |
|
|
FAAS
52
First Allied Advisory Services
San Diego,
California
| – | -$15K | -274 | Closed |
|
|
MAM
53
Meeder Asset Management
Dublin,
Ohio
| – | -$9K | -151 | Closed |
|
|
BEI
54
Benjamin Edwards Inc
Clayton,
Missouri
| – | -$1K | -21 | Closed |
|
PPH Hedge Fund Activity: Q4 2019 in Review
49 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q4 2019, worth a combined $206M — up 59% from $129M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new PPH positions and 5 closed out — a net gain of 6 holders — while 8 added to existing stakes and 13 trimmed.
The largest buyer was Credit Suisse, opening a new position worth an estimated $68.3M. The largest seller was Bank of America, cutting an estimated $48.3M.
- 49 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q4 2019, up from 43 in Q3 2019.
- Funds reported $206M of VanEck Pharmaceutical ETF stock for Q4 2019, up 59% quarter-over-quarter.
- 11 funds opened new VanEck Pharmaceutical ETF positions in Q4 2019 and 5 closed out, a net change of +6 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q4 2019 was Credit Suisse, an estimated $68.3M added.
- The largest VanEck Pharmaceutical ETF seller in Q4 2019 was Bank of America, an estimated $48.3M sold.
Based on aggregated 13F filings for Q4 2019.